Robbins LLP Reminds IMMP Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Immutep Limited

A class action lawsuit has been filed against Immutep Limited (IMMP) for allegedly misleading investors about the viability and efficacy of its TACTI-004 drug candidate. The company claimed strong operational progress in January 2026, but in March 2026, an Independent Data Monitoring Committee recommended discontinuing the Phase III trial for futility. The stock price plummeted 83% following the announcement, from $2.76 to $0.48 per share.